DNABy Calypso Research8 min read

Gingko Bioworks (DNA) Q4 2025 Earnings Analysis

A Rough Day for Gingko Bioworks: Q4 Revenue Misses and Stock Drops 27.4%

Key Takeaways

Gingko Bioworks (DNA) reported Q4 2025 earnings with revenue of $33M, representing a -23.8% year-over-year change. The stock moved -27.4% on earnings day.

The bull case: If Ginkgo successfully executes on autonomous labs, leveraging Datapoints and cloud lab to build recurring, higher-quality revenues while keeping cash burn within guidance, it can become the de facto infrastructure and data backbone for bio-AI and industrialized biotech R&D.

The bear case: If autonomous labs adoption is slower than expected, Datapoints and RAC deployments fail to scale into meaningful recurring revenue, and cash burn re-accelerates as capital is redirected from divested Biosecurity, Ginkgo could face dilution and structurally impaired profitability with a still-unproven business model.

Financial Highlights

  • Revenue: $33M (-23.8% YoY)
  • Gross Profit: $42M (124.4% margin, +46.3% YoY)
  • Operating Income: $-71M (-211.9% margin, +24.4% YoY)
  • Net Income: $-81M
  • TTM Revenue: $170M

Stock Performance

  • Earnings Day Move: -27.4%
  • Year-to-Date: -23.0%
  • 1-Year Return: -16.4%
  • vs. S&P 500 (since earnings): -22.8%
  • vs. Nasdaq (since earnings): -20.4%

View live DNA data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Gingko Bioworks's Q4 2025 earnings call:

Focus on Autonomous Labs vs. Traditional R&D Services and Revenue Guidance

Sentiment: Positive

"the focus of the team in 2026 is not on hitting a short-term revenue target around a service run on top of our autonomous lab... What I want their focus to be on is decommissioning all of the different labs here at Ginkgo and moving that work onto our autonomous lab so that we can show all of our customers that this works." — Jason Kelly
"For these reasons, in 2026, we will not be providing revenue guidance as we believe cash burn best reflects our continuing services and tools and further investments in autonomous labs." — Jason Kelly

Sustainability of Cash Burn Improvements and Capital Allocation to Autonomous Labs

Sentiment: Mixed

"Cash burn for the full year 2025 was $171 million, down from $383 million in 2024, a 55% decrease... For 2026, our overall expected cash burn guidance is to be in the range of $125 million to $150 million. This range reflects a firm balance amongst cost efficiency, continuing services and tools and the further investments we are making." — Steven Coen
"we are spending it very deliberately on autonomous Labs, and we're doing it in a controlled way. We're hopefully spending substantially less than we spent in the last year and our relative position there to our cash file, it looks pretty good. So from my standpoint, we have a solid margin of safety as we're investing to lead in this area of autonomous labs going forward." — Jason Kelly

Commercialization Path, Revenue Quality, and Recurrence from RACs / Autonomous Lab Offerings

Sentiment: Positive

"on top of that system, we'll do those services, right? So we'll have our data point service, our upcoming cloud lab service and then our Solution service... of the 3, I think Solutions is the one where you're really off hunting each time to add new research partnerships, but the other 2 are a bit more repeat business." — Jason Kelly
"when our robotics go in, there's an initial spend on CapEx, but then we have a service and software license that's ongoing over time that is also repeat, more like a SaaS business. And then if you were to... have like sort of specialized reagents... that would also be repeat business as well." — Jason Kelly

Demand, Traction, and Tailwinds for Datapoints and Bio‑AI Data Generation

Sentiment: Positive

"we've been growing this business where we run our robotics to generate big data sets against the designs of customers... we've now worked with 10 of the top 20, I think, or 30 top pharma customers just in the first year we launched this thing. So people are really excited about it." — Jason Kelly
"That side of the house has gotten tailwinds... there's a whole bunch of companies in the start-up side who are starting to partner with the large pharmas because they have great bio AI models. And the reason they have great bio AI models is they have proprietary data... we're definitely the right, I'd say, the leader in providing data sets to again to the large pharma, large biotechs." — Jason Kelly

Strategic Rationale and Financial Impact of the Biosecurity Divestiture

Sentiment: Mixed

"we'll be divesting our Biosecurity business. That allows me to focus Ginkgo's investment and our dollars really into autonomous labs and bring in other new investors to invest alongside us into Biosecurity... Ginkgo will still hold a minority position in that. So we get a piece of the upside of what we've built, but the investment needed to build that biosecurity prime doesn't need to come from the $430 million... we can focus that into autonomous Labs." — Jason Kelly
"We will also close our transaction for the Biosecurity business as announced and disclosed... For these reasons, in 2026, we will not be providing revenue guidance as we believe cash burn best reflects our continuing services and tools and further investments in autonomous labs." — Steven Coen

Bull Case

If Ginkgo successfully executes on autonomous labs, leveraging Datapoints and cloud lab to build recurring, higher-quality revenues while keeping cash burn within guidance, it can become the de facto infrastructure and data backbone for bio-AI and industrialized biotech R&D.

Bear Case

If autonomous labs adoption is slower than expected, Datapoints and RAC deployments fail to scale into meaningful recurring revenue, and cash burn re-accelerates as capital is redirected from divested Biosecurity, Ginkgo could face dilution and structurally impaired profitability with a still-unproven business model.

Looking Ahead

With revenue declining -23.8% year-over-year, investors will be watching for signs of a turnaround at Gingko Bioworks, particularly around focus on Autonomous Labs vs. Traditional R&D Services and Revenue Guidance. With operating margins at -211.9%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Gingko Bioworks's revenue in Q4 2025?

Gingko Bioworks reported Q4 2025 revenue of $33M, representing a -23.8% year-over-year change.

Did Gingko Bioworks beat earnings expectations in Q4 2025?

The stock declined -27.4% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: If Ginkgo successfully executes on autonomous labs, leveraging Datapoints and cloud lab to build recurring, higher-quality revenues while keeping cash burn within guidance, it can become the de facto infrastructure and data backbone for bio-AI and industrialized biotech R&D.

What is the bull case for DNA stock?

The bull case for DNA centers on: If Ginkgo successfully executes on autonomous labs, leveraging Datapoints and cloud lab to build recurring, higher-quality revenues while keeping cash burn within guidance, it can become the de facto infrastructure and data backbone for bio-AI and industrialized biotech R&D.

What is the bear case for DNA stock?

The bear case for DNA centers on: If autonomous labs adoption is slower than expected, Datapoints and RAC deployments fail to scale into meaningful recurring revenue, and cash burn re-accelerates as capital is redirected from divested Biosecurity, Ginkgo could face dilution and structurally impaired profitability with a still-unproven business model.

How has DNA stock performed since its Q4 2025 earnings?

DNA moved -27.4% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +22.8% since earnings. Year-to-date, the stock has returned -23.0%.

Browse all 400+ earnings reports →

Learn More

Analyze DNA in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Gingko Bioworks and 400+ other stocks, explore the full platform.

Open DNA on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.